Nasus Pharma (NSRX) touts faster NS002 epinephrine delivery vs EpiPen in Phase 2

Rhea-AI Filing Summary

Nasus Pharma reported positive top line Phase 2 results for NS002, its intranasal epinephrine powder for treating anaphylaxis. In 50 healthy adults, NS002 reached the critical 100 pg/mL epinephrine threshold with a median time of 1.69 minutes versus 3.42 minutes for EpiPen® (p=0.033), with higher proportions of subjects reaching this level within the first minutes.

The company highlighted approximately 50% higher epinephrine exposure in the first 10 minutes versus EpiPen®, similar peak concentrations, and consistent advantages with repeat dosing, all with no serious adverse events. Nasus plans to start a pivotal clinical study in the fourth quarter of 2026 and is hosting a conference call to discuss the data.

Positive

• NS002 shows faster early epinephrine delivery than EpiPen®, with median time to 100 pg/mL of 1.69 minutes versus 3.42 minutes and about 50% higher drug exposure in the first 10 minutes.
• Favorable Phase 2 safety profile was reported, with no serious adverse events and consistent pharmacokinetic advantages across single and repeat dosing, supporting progression to a pivotal study planned for the fourth quarter of 2026.

Negative

• None.

Insights

Biotech clinical development analyst

Phase 2 data show faster epinephrine delivery versus EpiPen with clean safety.

Nasus Pharma released Phase 2 results showing NS002, an intranasal epinephrine powder, reached the 100 pg/mL therapeutic threshold in a median of 1.69 minutes versus 3.42 minutes for EpiPen® (p=0.033). A higher share of participants hit this level at 2.5 and 5 minutes, and early 10‑minute exposure was about 50% higher.

The study also reported comparable peak epinephrine concentrations and a favorable safety profile with no serious adverse events. These findings support the company’s plan to move NS002 into a pivotal study in the fourth quarter of 2026, though outcomes from that trial and regulatory review will determine ultimate clinical and commercial relevance.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026 (Report No. 3)

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Press Release

On March 16, 2026, Nasus Pharma Ltd., issued a press release titled “Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

Investor Presentation

On March 16, 2026, the Company made available an updated corporate presentation on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2 to this Report of Foreign Private Issuer on Form 6-K.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release issued on March 16, 2026, by Nasus Pharma Ltd. titled “Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold.”
99.2		Corporate Presentation, dated March 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
Date: March 16, 2026	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer

Exhibit 99.1

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen®

NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants

Pivotal study initiation planned for fourth quarter of 2026 

Conference call and webcast scheduled for 8:00 a.m. EDT today

TEL AVIV, Israel, March 16, 2026 — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive top line results from its Phase 2 clinical study of NS002, the Company’s investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The comprehensive analysis demonstrated that NS002 achieved significantly faster and higher early epinephrine absorption compared to intramuscular EpiPen® autoinjector. The Company plans to initiate its pivotal clinical study in fourth quarter  of 2026.

The open-label Phase 2 study enrolled 50 healthy adults with a history of allergic rhinitis. All subjects received a single and repeat dose of NS002 and intramuscular EpiPen^® with and without a nasal allergic challenge (“NAC”). This robust study design provided comprehensive data supporting NS002’s clinical utility across multiple administration scenarios that patients may encounter during actual anaphylactic emergencies.

“We’ve successfully demonstrated NS002’s differentiated and potentially superior product profile compared to traditional epinephrine autoinjectors,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “NS002 was specifically engineered for superior epinephrine delivery, powered by our proprietary Nasax® powder platform, and designed as a needle-free, easy to use and carry device. The compelling top line data significantly strengthens our conviction that NS002 has the potential to become a leading product in anaphylaxis treatment. These positive results represent a major milestone for Nasus Pharma as we advance NS002 towards the pivotal study and future marketing applications. We remain on track to initiate our pivotal study in the fourth quarter of 2026, bringing us closer to delivering this potentially life-saving innovation to patients worldwide.”

Top Line Analysis Key Results:

The top line Phase 2 analysis demonstrated multiple significant advantages for NS002 across key pharmacokinetic and pharmacodynamic parameters:

	●	Speed to Therapeutic Threshold: After a single administration, NS002 achieved the critical 100 pg/mL plasma epinephrine threshold with a median T100 of 1.69 minutes versus 3.42 minutes for EpiPen® (p=0.033). At 2.5 minutes, 67.4% of participants receiving NS002 reached the therapeutic threshold compared to 27.1% with EpiPen® (p=0.0001). At 5 minutes, 88.4% of NS002 subjects reached the threshold compared to 64.6% with EpiPen® (p=0.0081). By 10 minutes, approximately 95% of participants receiving NS002 reached the therapeutic threshold.
	●	Time to Peak Concentration: NS002 reached peak concentration (“Tmax”) in a median of 15 minutes compared to 19.8 minutes with EpiPen®, demonstrating consistently faster epinephrine delivery.
	●	Critical Window Drug Exposure: Total epinephrine absorption in the critical 10-minute therapeutic window following administration was approximately 50% higher with NS002, with AUC statistically significantly higher in the first 5–10 minutes compared to EpiPen®.
	●	Repeat Dose Performance: Repeat administration of NS002 with or without a NAC maintained consistent pharmacokinetic advantages over EpiPen®, a clinically significant finding given that patients experiencing severe anaphylaxis may require a repeat dose to fully resolve symptoms.
	●	Peak Plasma Concentrations: Across multiple scenarios, NS002 demonstrated comparable peak plasma concentration (“Cmax”) compared to EpiPen®, with repeat dosing showing particularly strong performance.
	●	Safety and Tolerability Profile: NS002 demonstrated a favorable safety and tolerability profile consistent with previous studies, with no serious adverse events reported.

These results demonstrated that NS002 has the potential to exceed EpiPen® performance across the full spectrum of real-world conditions, including the challenging NAC environment that simulates scenarios patients may encounter during actual allergic reactions. The analysis showed statistically significant improvements in time to therapeutic threshold (T100) and in the proportion of subjects reaching the therapeutic epinephrine threshold within the first minutes following administration.

Conference call and webcast

Nasus Pharma will host a conference call and webcast today at 8:00 a.m. EDT to review and discuss the final analysis data from the Phase 2 repeated dose clinical study. Individuals may dial in to the conference call by dialing 1-877-704-4453 from the U.S. or by dialing +1-201-389-0920 from outside the U.S., or view the webcast HERE. A replay of the webcast will be hosted on Nasus Pharma’s investor relations website at https://ir.nasuspharma.com/investors/events/.

About Nasus Pharma

Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the belief that the full analysis from the Phase 2 clinical study demonstrates NS002’s superior epinephrine delivery compared to traditional epinephrine autoinjectors; the belief that NS002 has the potential to become a leading product in anaphylaxis treatment; the expectation that the top line data from the Phase 2 study will support advancement of NS002 toward a pivotal study and future marketing applications; the potential of NS002 to exceed EpiPen® performance across the full spectrum of real-world conditions, including the challenging NAC environment that simulates scenarios patients may encounter during actual allergic reactions and, the timing of initiating its pivotal clinical study in the fourth quarter of 2026 . Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Registration Statement on Form F-1 filed with the U.S. Securities and Exchange Commission on March 2, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact

Nasus Pharma Ltd.

info@nasuspharma.com

Investor Contact

Mike Moyer

LifeSci Advisors

+1-617-308-4306

mmoyer@lifesciadvisors.com

Exhibit 99.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FAQ

What did Nasus Pharma (NSRX) announce about its NS002 Phase 2 trial?

Nasus Pharma reported positive top line Phase 2 results for NS002, its intranasal epinephrine powder. The company said NS002 delivered epinephrine faster than EpiPen®, maintained comparable peak levels, and showed no serious adverse events, supporting advancement toward a pivotal trial.

How did NS002 perform versus EpiPen in reaching therapeutic epinephrine levels?

NS002 reached the 100 pg/mL therapeutic epinephrine threshold in a median of 1.69 minutes versus 3.42 minutes for EpiPen® (p=0.033). A higher proportion of NS002 subjects achieved this level at 2.5 and 5 minutes, indicating faster early systemic exposure in this study.

What safety results were reported for Nasus Pharma’s NS002 in Phase 2?

The Phase 2 study reported a favorable safety and tolerability profile for NS002, with no serious adverse events. Pharmacodynamic responses were comparable to EpiPen® across participants, and repeat dosing maintained its pharmacokinetic advantages, supporting further clinical development plans.

When does Nasus Pharma plan to start the pivotal study for NS002?

Nasus Pharma stated it intends to initiate the pivotal clinical study of NS002 in the fourth quarter of 2026. The recently reported Phase 2 results are expected to support this next-stage trial and future marketing applications if subsequent data remain supportive.

What is NS002 and how is it intended to be used for anaphylaxis?

NS002 is an investigational intranasal epinephrine powder product candidate designed as a needle-free alternative to epinephrine autoinjectors for anaphylaxis. It uses Nasus Pharma’s proprietary powder-based intranasal technology to enable rapid absorption through the nasal cavity’s vascular network.

Did the NS002 Phase 2 study include repeat dosing or only single doses?

The open-label Phase 2 trial included both single and repeat dosing of NS002 and EpiPen®, with and without a nasal allergic challenge. NS002 maintained pharmacokinetic advantages over EpiPen® in repeat-dose scenarios, which may be relevant for severe anaphylaxis requiring additional doses.

Filing Exhibits & Attachments

47 documents

Press Releases

• EX-99.1 EX-99.1 23.8 KB
• EX-99.2 EX-99.2 28.2 KB
• EX-99 GRAPHIC 12.4 KB
• EX-99 GRAPHIC 840.9 KB
• EX-99 GRAPHIC 1.1 MB
• EX-99 GRAPHIC 450.4 KB
• EX-99 GRAPHIC 331.3 KB
• EX-99 GRAPHIC 856.0 KB
• EX-99 GRAPHIC 847.3 KB
• EX-99 GRAPHIC 677.8 KB
• EX-99 GRAPHIC 431.7 KB
• EX-99 GRAPHIC 538.9 KB
• EX-99 GRAPHIC 353.7 KB
• EX-99 GRAPHIC 508.4 KB
• EX-99 GRAPHIC 521.0 KB
• EX-99 GRAPHIC 957.5 KB
• EX-99 GRAPHIC 488.7 KB
• EX-99 GRAPHIC 492.4 KB
• EX-99 GRAPHIC 307.3 KB
• EX-99 GRAPHIC 278.1 KB
• EX-99 GRAPHIC 127.3 KB
• EX-99 GRAPHIC 364.2 KB
• EX-99 GRAPHIC 234.2 KB
• EX-99 GRAPHIC 417.7 KB
• EX-99 GRAPHIC 374.0 KB
• EX-99 GRAPHIC 453.0 KB
• EX-99 GRAPHIC 424.8 KB
• EX-99 GRAPHIC 403.7 KB
• EX-99 GRAPHIC 547.9 KB
• EX-99 GRAPHIC 667.2 KB
• EX-99 GRAPHIC 1.0 MB
• EX-99 GRAPHIC 837.0 KB
• EX-99 GRAPHIC 917.5 KB
• EX-99 GRAPHIC 265.2 KB
• EX-99 GRAPHIC 374.4 KB
• EX-99 GRAPHIC 265.1 KB
• EX-99 GRAPHIC 380.9 KB
• EX-99 GRAPHIC 449.8 KB
• EX-99 GRAPHIC 938.5 KB
• EX-99 GRAPHIC 339.0 KB
• EX-99 GRAPHIC 337.1 KB
• EX-99 GRAPHIC 288.6 KB
• EX-99 GRAPHIC 306.0 KB
• EX-99 GRAPHIC 406.8 KB
• EX-99 GRAPHIC 430.7 KB
• EX-99 GRAPHIC 681.2 KB
• EX-99 GRAPHIC 410.1 KB